Loop Capital analyst Joseph France raised the firm’s price target on HCA Healthcare to $285 from $240 and keeps a Buy rating on the shares. The company’s Q4 results were "solid" and its 2024 growth should return to more normal long-term trends after enduring headwinds in 2023, the analyst tells investors in a research note. The firm also states that it was impressed with the company’s progress on staffing, where a quick fix could accelerate HCA’s recovery from the pandemic.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $290 from $270 at Truist
- HCA Healthcare price target raised to $292 from $238 at Cowen
- HCA Healthcare price target raised to $279 from $265 at Mizuho
- HCA Healthcare price target raised to $293 from $280 at Citi
- HCA Healthcare sees FY23 EPS $16.40-$17.60, consensus $18.23